Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

TUBB1 mutations cause thyroid dysgenesis associated with abnormal platelet physiology

Open access

Abstract

The genetic causes of congenital hypothyroidism due to thyroid dysgenesis (TD) remain largely unknown.We identified three novel TUBB1 gene mutations that co-segregated with TD in three distinct families leading to 1.1% of TUBB1 mutations in TD study cohort.TUBB1 (Tubulin, Beta 1 Class VI) encodes for a member of the btubulin protein family.TUBB1 gene is expressed in the developing and adult thyroid in humans and mice.All three TUBB1 mutations lead to non-functional a/b-tubulin dimers that cannot be incorporated into microtubules.In mice, Tubb1 knock-out disrupted microtubule integrity by preventing b1-tubulin incorporation and impaired thyroid migration and thyroid hormone secretion.In addition, TUBB1 mutations caused the formation of macroplatelets and hyperaggregation of human platelets after stimulation by low doses of agonists.Our data highlight unexpected roles for b1tubulin in thyroid development and in platelet physiology.Finally, these findings expand the spectrum of the rare paediatric diseases related to mutations in tubulin-coding genes and provide new insights into the genetic background and mechanisms involved in congenital hypothyroidism and thyroid dysgenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201809569

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Pedigrees and clinical table Pedigrees of three families with TUBB1 mutations. Family F1 has three affected individuals with homozygous mutations, family F2 has two affected individuals with heterozygous mutations, and family F3 has two affected individuals with heterozygous mutations. Thus, all seven patients (P1–P7) carry at least one mutated allele and have thyroid dysgenesis (TD) and macroplatelets. The patients are represented with filled symbols and unaffected family members with open symbols. NA, not available thyroid ultrasonography; *mild thyroid asymmetry (possibly normal) with normal thyroid function; N, not mutated; m, mutated.
Figure 1 Pedigrees and clinical table Pedigrees of three families with TUBB1 mutations. Family F1 has three affected individuals with homozygous mutations, family F2 has two affected individuals with heterozygous mutations, and family F3 has two affected individuals with heterozygous mutations. Thus, all seven patients (P1–P7) carry at least one mutated allele and have thyroid dysgenesis (TD) and macroplatelets. The patients are represented with filled symbols and unaffected family members with open symbols. NA, not available thyroid ultrasonography; *mild thyroid asymmetry (possibly normal) with normal thyroid function; N, not mutated; m, mutated.CC BY · PubMed Central
Figure 2 Molecular genetics AAlignment and conservation of residues encoded by TUBB1 orthologues and genes encoding for other β‐tubulins (TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB5, TUBB6 and TUBB8). Mutations are shown in green. Mutated aminoacids through species or through all TUBB are shown in red boxes.BLocation of TUBB1 mutations in the cDNA and of the corresponding changes in the protein. Exons are represented by boxes numbered from 1 to 4. The dark grey box represents the protein domain responsible for encoding guanosine triphosphate (GTP) and the light grey box the domain for microtubule‐associated protein (MAP) binding. The arrows show the consequences of the three TUBB1 mutations in our patients, all of which are in the GTP domain. Mutations of this study are in bold, and published mutations associated with congenital macrothrombocytopaenia are in italic.
Figure 2 Molecular genetics AAlignment and conservation of residues encoded by TUBB1 orthologues and genes encoding for other β‐tubulins (TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB5, TUBB6 and TUBB8). Mutations are shown in green. Mutated aminoacids through species or through all TUBB are shown in red boxes.BLocation of TUBB1 mutations in the cDNA and of the corresponding changes in the protein. Exons are represented by boxes numbered from 1 to 4. The dark grey box represents the protein domain responsible for encoding guanosine triphosphate (GTP) and the light grey box the domain for microtubule‐associated protein (MAP) binding. The arrows show the consequences of the three TUBB1 mutations in our patients, all of which are in the GTP domain. Mutations of this study are in bold, and published mutations associated with congenital macrothrombocytopaenia are in italic.CC BY · PubMed Central
Figure 3 β1‐tubulin expression in the developing thyroid and deleterious effect of TUBB1 mutations A TUBB1 is expressed in the developing human thyroid at 8 gestational weeks (GW), 10 GW and 12 GW and in the adult human thyroid: quantitative PCR results normalized to one of three thyroid tissues at 8 GW value (in black) and peptidylprolyl isomerase A. Experiments with four tissues per stage. Results are reported as mean ± SEM. Statistical comparisons versus 8 GW (in black) using ANOVA test showed no significant differences.B Tubb1 is expressed in the developing mouse thyroid at E13.5, E15.5 and E17.5 and in the adult mouse thyroid: quantitative PCR results normalized to one of three thyroid tissues at E13.5 value and peptidylprolyl isomerase A. Experiments with four tissues per stage. Results are reported as mean ± SEM. Statistical comparisons versus E13.5 (black), **P < 0.01 using ANOVA test.CSorted mouse thyroid cells, Tubb1 expression in endothelial cells (Pecam‐positive cells), epithelial cells (EpCAM), fibroblasts (Pdgfra) and leucocytes (CD45) at E17.5 and adulthood: quantitative PCR results (normalized to EpCAM‐positive cells at adult stage and peptidylprolyl isomerase A). Mean ± SEM of three independent cell‐sorting experiments. Statistical comparisons versus epithelial cells (in black) at each stage, *P < 0.05, ***P < 0.001 using ANOVA test.DImmunohistofluorescence of β1‐tubulin (in red), thyroglobulin (TG, in green) and both merged (from left to right) at 12 GW in human thyroid tissue. The boxes delineate the enlarged areas shown below.EStructural representation of wild‐type and p.P160L mutated β1‐tubulin showing the change in conformation surrounding helix H4. Top: proline at position 160 in pink; bottom: substituting leucine at the same position in blue.FLocalization of transfected Myc‐tagged wild‐type and mutant (P160L) β1‐tubulin in Nthy cells. Immunostaining with anti‐Myc antibody (in green) and microtubule cytoskeleton stained with α‐tubulin antibody (in red). Note that β1‐tubulin ‐P160L is found throughout the cytoplasm showing puncta appearance, whereas wild‐type β1‐tubulin colocalizes with the microtubules.
Figure 3 β1‐tubulin expression in the developing thyroid and deleterious effect of TUBB1 mutations A TUBB1 is expressed in the developing human thyroid at 8 gestational weeks (GW), 10 GW and 12 GW and in the adult human thyroid: quantitative PCR results normalized to one of three thyroid tissues at 8 GW value (in black) and peptidylprolyl isomerase A. Experiments with four tissues per stage. Results are reported as mean ± SEM. Statistical comparisons versus 8 GW (in black) using ANOVA test showed no significant differences.B Tubb1 is expressed in the developing mouse thyroid at E13.5, E15.5 and E17.5 and in the adult mouse thyroid: quantitative PCR results normalized to one of three thyroid tissues at E13.5 value and peptidylprolyl isomerase A. Experiments with four tissues per stage. Results are reported as mean ± SEM. Statistical comparisons versus E13.5 (black), **P < 0.01 using ANOVA test.CSorted mouse thyroid cells, Tubb1 expression in endothelial cells (Pecam‐positive cells), epithelial cells (EpCAM), fibroblasts (Pdgfra) and leucocytes (CD45) at E17.5 and adulthood: quantitative PCR results (normalized to EpCAM‐positive cells at adult stage and peptidylprolyl isomerase A). Mean ± SEM of three independent cell‐sorting experiments. Statistical comparisons versus epithelial cells (in black) at each stage, *P < 0.05, ***P < 0.001 using ANOVA test.DImmunohistofluorescence of β1‐tubulin (in red), thyroglobulin (TG, in green) and both merged (from left to right) at 12 GW in human thyroid tissue. The boxes delineate the enlarged areas shown below.EStructural representation of wild‐type and p.P160L mutated β1‐tubulin showing the change in conformation surrounding helix H4. Top: proline at position 160 in pink; bottom: substituting leucine at the same position in blue.FLocalization of transfected Myc‐tagged wild‐type and mutant (P160L) β1‐tubulin in Nthy cells. Immunostaining with anti‐Myc antibody (in green) and microtubule cytoskeleton stained with α‐tubulin antibody (in red). Note that β1‐tubulin ‐P160L is found throughout the cytoplasm showing puncta appearance, whereas wild‐type β1‐tubulin colocalizes with the microtubules.CC BY · PubMed Central
Figure 4 Tubb1 −/− mice have abnormal thyroid development AThyroid morphology was investigated using Nkx2‐1 staining at E9.5 and E11.5 (sagittal sections) and at E13.5, E15.5 and E17.5 (transverse sections) in wild‐type (wt) and Tubb1 −/− littermates. Nkx2‐1 was used as a marker of early thyrocyte progenitors and differentiated thyrocytes. Delays in thyroid migration and in fusion of the median anlage to the ultimobranchial bodies were observed at E11.5 and E13.5 (arrow), respectively, in Tubb1 −/− mice. At E11.5, stained migrating thyroid cells were visible along the tract only in Tubb1 −/− littermates (arrow). At E17.5, a pyramidal lobe was visible in Tubb1 −/− littermates (arrow). tr: trachea; ub: ultimobranchial body. Scale bar: 50 μm.BTotal thyroid surface area (μm2) was quantified using Nkx2‐1 staining at each embryonic stage. Top: thyroid surface area normalized for weight of each embryo. Four mice were analysed per genotype at E9.5 and five mice at E11.5. Bottom: thyroid surface area in μm2. Four mice were analysed per genotype at E9.5, five at E11.5, six at E13.5, four at E15.5 and three at E17.5. Right: proliferation ratio calculated as the proportion of Nkx2‐1‐positive cells labelled with Ki67 at E9.5 in wt and Tubb1 −/− thyroid anlages. Four mice were analysed for wild‐type genotype and five for Tubb1 −/−. ma: median anlage. Note that the thyroid ma is larger and the proliferation ratio higher at E.9.5 in Tubb1 −/− mice, whereas from E13.5 onwards the Tubb1 −/− thyroids were hypoplastic. Wt in black, KO, Tubb1 −/− in grey.CThyroid marker expression by quantitative PCR in thyroid tissue at E15.5 and E17.5 in Tubb1 −/− versus wt mice normalized for peptidylprolyl isomerase A. Note the decreases in thyroid differentiation markers at E15.5 and E17.5 and also in thyroid transcription factors at E17.5. Four mice were analysed per genotype at E15.5 and three at E17.5.DStaining of Nkx2‐1 and T4 at E17.5 and surface area quantification demonstrating T4 retention in Tubb1 −/− versus wt thyroids. The data are the percentage of T4 or calcitonin (CT) surface area versus total thyroid area (estimated from the Nkx2‐1‐stained surface area). Three mice were analysed per genotype. Scale bar: 50 μm.Data information: Results are reported as mean ± SEM. Student's t‐test, *P < 0.05, **P < 0.01 and ***P < 0.001.
Figure 4 Tubb1 −/− mice have abnormal thyroid development AThyroid morphology was investigated using Nkx2‐1 staining at E9.5 and E11.5 (sagittal sections) and at E13.5, E15.5 and E17.5 (transverse sections) in wild‐type (wt) and Tubb1 −/− littermates. Nkx2‐1 was used as a marker of early thyrocyte progenitors and differentiated thyrocytes. Delays in thyroid migration and in fusion of the median anlage to the ultimobranchial bodies were observed at E11.5 and E13.5 (arrow), respectively, in Tubb1 −/− mice. At E11.5, stained migrating thyroid cells were visible along the tract only in Tubb1 −/− littermates (arrow). At E17.5, a pyramidal lobe was visible in Tubb1 −/− littermates (arrow). tr: trachea; ub: ultimobranchial body. Scale bar: 50 μm.BTotal thyroid surface area (μm2) was quantified using Nkx2‐1 staining at each embryonic stage. Top: thyroid surface area normalized for weight of each embryo. Four mice were analysed per genotype at E9.5 and five mice at E11.5. Bottom: thyroid surface area in μm2. Four mice were analysed per genotype at E9.5, five at E11.5, six at E13.5, four at E15.5 and three at E17.5. Right: proliferation ratio calculated as the proportion of Nkx2‐1‐positive cells labelled with Ki67 at E9.5 in wt and Tubb1 −/− thyroid anlages. Four mice were analysed for wild‐type genotype and five for Tubb1 −/−. ma: median anlage. Note that the thyroid ma is larger and the proliferation ratio higher at E.9.5 in Tubb1 −/− mice, whereas from E13.5 onwards the Tubb1 −/− thyroids were hypoplastic. Wt in black, KO, Tubb1 −/− in grey.CThyroid marker expression by quantitative PCR in thyroid tissue at E15.5 and E17.5 in Tubb1 −/− versus wt mice normalized for peptidylprolyl isomerase A. Note the decreases in thyroid differentiation markers at E15.5 and E17.5 and also in thyroid transcription factors at E17.5. Four mice were analysed per genotype at E15.5 and three at E17.5.DStaining of Nkx2‐1 and T4 at E17.5 and surface area quantification demonstrating T4 retention in Tubb1 −/− versus wt thyroids. The data are the percentage of T4 or calcitonin (CT) surface area versus total thyroid area (estimated from the Nkx2‐1‐stained surface area). Three mice were analysed per genotype. Scale bar: 50 μm.Data information: Results are reported as mean ± SEM. Student's t‐test, *P < 0.05, **P < 0.01 and ***P < 0.001.CC BY · PubMed Central
Figure 5 Tubb1 −/− mice have altered thyroid function with impaired hormone secretion ASerum TSH and T4 levels in 3‐month‐old Tubb1 −/− and wild‐type mice. Numbers of animals tested were 10 wild‐type males and 14 Tubb1 −/− males for TSH and for 14 wild‐type and 22 Tubb1 −/−males for T4. Tubb1 −/− mice had hypothyroidism with elevated TSH and decreased T4 versus wild‐type mice.BNkx2‐1 (in brown) immunostaining of adult thyroid tissue. Note the disorganization of the thyroid tissue in Tubb1 −/− versus wild‐type mice.CUltrastructural alterations shown by electron microscopy in wild‐type and Tubb1 −/− thyroid tissues. In Tubb1 −/− tissues, note the disorganization of secretion vesicles (white asterisks) and rods of identical density to secretion vesicles (white arrow). The ER is considerably dilated in Tubb1 −/− thyrocytes. Representative views. Scale bars at the bottom left for each view. Co: colloid.DER stress in Tubb1 −/− thyroid tissue. Top: Chop and XBPs expression by quantitative PCR in adults, normalized to peptidylprolyl isomerase A. Experiments with four tissues per stage for each genotype; wt in black and Tubb1 −/− in grey. Bottom: Chop and Actin protein expression by Western blotting in three representative wild‐type and Tubb1 −/− mice. The Chop band quantification normalized for Actin confirms the increased Chop expression demonstrated by quantitative PCR in Tubb1 −/− versus wild‐type thyroids. All lanes are from the same blot, which was cut where indicated.ECo‐immunostaining of endoplasmic reticulum (ER) marker (KDEL, in red), thyroglobulin (Tg in green) and both merged (from left to right) in adult thyroid tissue. Note the thyrocyte disorganization in Tubb1 −/− mice.Data information: Results are reported as mean ± SEM. Student's t‐test, *P < 0.05, **P < 0.01.Source data are available online for this figure.
Figure 5 Tubb1 −/− mice have altered thyroid function with impaired hormone secretion ASerum TSH and T4 levels in 3‐month‐old Tubb1 −/− and wild‐type mice. Numbers of animals tested were 10 wild‐type males and 14 Tubb1 −/− males for TSH and for 14 wild‐type and 22 Tubb1 −/−males for T4. Tubb1 −/− mice had hypothyroidism with elevated TSH and decreased T4 versus wild‐type mice.BNkx2‐1 (in brown) immunostaining of adult thyroid tissue. Note the disorganization of the thyroid tissue in Tubb1 −/− versus wild‐type mice.CUltrastructural alterations shown by electron microscopy in wild‐type and Tubb1 −/− thyroid tissues. In Tubb1 −/− tissues, note the disorganization of secretion vesicles (white asterisks) and rods of identical density to secretion vesicles (white arrow). The ER is considerably dilated in Tubb1 −/− thyrocytes. Representative views. Scale bars at the bottom left for each view. Co: colloid.DER stress in Tubb1 −/− thyroid tissue. Top: Chop and XBPs expression by quantitative PCR in adults, normalized to peptidylprolyl isomerase A. Experiments with four tissues per stage for each genotype; wt in black and Tubb1 −/− in grey. Bottom: Chop and Actin protein expression by Western blotting in three representative wild‐type and Tubb1 −/− mice. The Chop band quantification normalized for Actin confirms the increased Chop expression demonstrated by quantitative PCR in Tubb1 −/− versus wild‐type thyroids. All lanes are from the same blot, which was cut where indicated.ECo‐immunostaining of endoplasmic reticulum (ER) marker (KDEL, in red), thyroglobulin (Tg in green) and both merged (from left to right) in adult thyroid tissue. Note the thyrocyte disorganization in Tubb1 −/− mice.Data information: Results are reported as mean ± SEM. Student's t‐test, *P < 0.05, **P < 0.01.Source data are available online for this figure.CC BY · PubMed Central
Figure 6 TUBB1 mutations induce abnormal platelet formation or macroplatelets ARepresentative blood smears of patients with TUBB1 mutations (P1 and P3 homozygous for p.P160L, P4 heterozygous for p.Y106X, and P6 and P7 heterozygous for c.35delG) after May–Grünwald–Giemsa staining. Variable platelet size in patients was observed with all three mutations with the presence of macroplatelets (arrows).BTransmission electron microscopy (TEM) analysis of platelet ultrastructure in the patients. The results confirm the abnormal platelet morphology.CRepresentative images of proplatelet formation in P1 and P4. Cultured control and patient megakaryocytes (MKs) after thrombopoietin‐induced differentiation were spread over a BSA‐coated coverslip on day 10. On day 13 or 14, MKs were fixed (4% paraformaldehyde) and proplatelet structure was observed after β‐tubulin staining. Scale bars: 20 μm. Only P1 and P4 could be studied. The graphs show the mean ± SEM of the shaft thickness of proplatelet extensions (left) and the diameter of coiled elements (right) of the future proplatelets, both of which were significantly increased in the patients, indicating that the TUBB1 mutations (homozygous p.P160L and heterozygous p.Y106X) affected proplatelet morphology. Statistical significance was determined by one‐way ANOVA, followed by Dunnett's multiple comparisons test (*P < 0.05, ***P < 0.001; 20–60 MKs were analysed/patient).
Figure 6 TUBB1 mutations induce abnormal platelet formation or macroplatelets ARepresentative blood smears of patients with TUBB1 mutations (P1 and P3 homozygous for p.P160L, P4 heterozygous for p.Y106X, and P6 and P7 heterozygous for c.35delG) after May–Grünwald–Giemsa staining. Variable platelet size in patients was observed with all three mutations with the presence of macroplatelets (arrows).BTransmission electron microscopy (TEM) analysis of platelet ultrastructure in the patients. The results confirm the abnormal platelet morphology.CRepresentative images of proplatelet formation in P1 and P4. Cultured control and patient megakaryocytes (MKs) after thrombopoietin‐induced differentiation were spread over a BSA‐coated coverslip on day 10. On day 13 or 14, MKs were fixed (4% paraformaldehyde) and proplatelet structure was observed after β‐tubulin staining. Scale bars: 20 μm. Only P1 and P4 could be studied. The graphs show the mean ± SEM of the shaft thickness of proplatelet extensions (left) and the diameter of coiled elements (right) of the future proplatelets, both of which were significantly increased in the patients, indicating that the TUBB1 mutations (homozygous p.P160L and heterozygous p.Y106X) affected proplatelet morphology. Statistical significance was determined by one‐way ANOVA, followed by Dunnett's multiple comparisons test (*P < 0.05, ***P < 0.001; 20–60 MKs were analysed/patient).CC BY · PubMed Central
Figure 7 TUBB1 mutations alter protein expression in platelets and platelet functions ARelative expression of α‐tubulin and β1‐tubulin in platelets from P1 and P3 (homozygous p.P160L), P4 (heterozygous p.Y106X), and P6 and P7 (heterozygous c.35delG) was quantified by Western blotting using specific antibodies against α‐tubulin or β1‐tubulin. With both mutations, α‐tubulin expression was normal but β1‐tubulin expression was significantly decreased. The β1‐tubulin antibody recognizes C‐terminal domain.BαIIbβ3 integrin activation was evaluated by flow cytometry (% of positive platelets and mean fluorescence intensity) in whole blood from P1 and P3 (homozygous p.P160L) and from P6 and P7 (heterozygous c.35delG); P4 could not be studied. While no αIIbβ3 integrin activations were detected in P6 and P7 (family 3), P1 and P3 (family 1) exhibited a significant increase in αIIbβ3 activation, indicating basal platelet activation.CAggregation of washed platelets induced by ADP (5 or 10 μM) or collagen (0.6, 0.8 or 2 μg/ml) was evaluated in at least one member of each family. Patients from families 1 and 2 had increased platelet aggregation in response to low doses of agonist versus controls, suggesting that TUBB1 affected by homozygous p.P160L and heterozygous p.Y106X mutations affected platelet function. Platelet aggregation to both agonists was normal in both patients from family 3 (heterozygous c.35delG).Data information: Results are reported as mean ± SEM. Family F1, n = 3 independent experiments; Family F2, n = 1 experiment; Family F3, n = 2 independent experiments. Statistical significance was determined by one‐way ANOVA, followed by Dunnett's multiple comparisons test (*P < 0.05, **P < 0.01, ***P < 0.001, nd: statistical significance not determined because n ≤ 2).
Figure 7 TUBB1 mutations alter protein expression in platelets and platelet functions ARelative expression of α‐tubulin and β1‐tubulin in platelets from P1 and P3 (homozygous p.P160L), P4 (heterozygous p.Y106X), and P6 and P7 (heterozygous c.35delG) was quantified by Western blotting using specific antibodies against α‐tubulin or β1‐tubulin. With both mutations, α‐tubulin expression was normal but β1‐tubulin expression was significantly decreased. The β1‐tubulin antibody recognizes C‐terminal domain.BαIIbβ3 integrin activation was evaluated by flow cytometry (% of positive platelets and mean fluorescence intensity) in whole blood from P1 and P3 (homozygous p.P160L) and from P6 and P7 (heterozygous c.35delG); P4 could not be studied. While no αIIbβ3 integrin activations were detected in P6 and P7 (family 3), P1 and P3 (family 1) exhibited a significant increase in αIIbβ3 activation, indicating basal platelet activation.CAggregation of washed platelets induced by ADP (5 or 10 μM) or collagen (0.6, 0.8 or 2 μg/ml) was evaluated in at least one member of each family. Patients from families 1 and 2 had increased platelet aggregation in response to low doses of agonist versus controls, suggesting that TUBB1 affected by homozygous p.P160L and heterozygous p.Y106X mutations affected platelet function. Platelet aggregation to both agonists was normal in both patients from family 3 (heterozygous c.35delG).Data information: Results are reported as mean ± SEM. Family F1, n = 3 independent experiments; Family F2, n = 1 experiment; Family F3, n = 2 independent experiments. Statistical significance was determined by one‐way ANOVA, followed by Dunnett's multiple comparisons test (*P < 0.05, **P < 0.01, ***P < 0.001, nd: statistical significance not determined because n ≤ 2).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Research works printed but not linked: 1

  1. Rousset B, Dupuy C, Miot F, Dumont J (2015) Chapter 2 thyroid hormone synthesis and secretion. In Endotext, De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A (eds), pp 2000–2015. South Dartmouth, MA: MDText.com Inc.

Cited by

See all 76

Metadata

Authors
Stoupa, A., Adam, F., Kariyawasam, D., Strassel, C., Gawade, S., Szinnai, G., Kauskot, A., Lasne, D., Janke, C., Natarajan, K., Schmitt, A., Bole‐Feysot, C., Nitschke, P., Léger, J., Jabot‐Hanin, F., Tores, F., Michel, A., Munnich, A., Besmond, C., Scharfmann, R., Lanza, F., Borgel, D., Polak, M., & Carré, A.
Affiliations
  • Hôpital Necker-Enfants Malades (FR)
  • Inserm (FR)
  • University of Basel (CH)
  • Université Paris-Sud (FR)
  • Institut des Maladies Génétiques Imagine (FR)
Corresponding author
Carré, Aurore
Venue
EMBO Molecular Medicine
Published
2018-11-19
Volume
10
Issue
12
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2901380890
Cited by
71
References
75
Citations by year
2026: 8 · 2025: 8 · 2024: 8 · 2023: 5 · 2022: 16 · 2021: 15 · 2020: 6 · 2019: 5
FWCI
5.17
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, other-oa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Fondation pour la Recherche Medicale (SPF20140129173)
  • Princess Grace Foundation of Monaco
  • Assistance Publique – Hôpitaux de Paris (P11012‐IDRCB 2012‐A00797‐36)
  • Agence Nationale de la Recherche (ANR‐10‐LBX‐0038, ANR‐10‐IDEX‐0001‐02 PSL)
  • Électricité de France
  • Novartis | Sandoz
  • Merck KGaA | EMD Serono
  • European Society for Paediatric Endocrinology
  • Alexander S. Onassis Public Benefit Foundation
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
TUBB1, beta-tubulin, thyroid dysgenesis, congenital hypothyroidism, platelet hyperaggregability, microtubule integrity, thyroid development, thyroid hormone secretion, tubulin mutations
MeSH terms
Animals, Blood Platelets, Humans, Mutation, Platelet Aggregation, Tubulin, Mice, Knockout, Thyroid Dysgenesis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TUBB1 mutations cause thyroid dysgenesis associated with abnormal platelet physiology. https://app.cochat.ai/papers/10.15252/emmm.201809569
The paper
Stoupa, A., Adam, F., Kariyawasam, D., Strassel, C., Gawade, S., Szinnai, G., Kauskot, A., Lasne, D., Janke, C., Natarajan, K., Schmitt, A., Bole‐Feysot, C., Nitschke, P., Léger, J., Jabot‐Hanin, F., Tores, F., Michel, A., Munnich, A., Besmond, C., . . . Carré, A. (2018). TUBB1 mutations cause thyroid dysgenesis associated with abnormal platelet physiology. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201809569

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.